GlassScriptPhysician profile
Juan G Camayd
NPI 1124004577
$6,738.54
in general payments reported to CMS, 2019-2025
32 companies · $92.32 in 2025
The $92.32 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,760 · 2020: $1,415 · 2021: $1,459 · 2022: $947 · 2023: $662 · 2024: $404 · 2025: $92.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085 · Education: $72.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.18 |
| Education | $72.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $894.70 | 2019-2023 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $807.38 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $611.18 | 2019-2024 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $598.42 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Lilly USA, LLC | $568.57 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $538.44 | 2019-2020 | |
| Amgen INC. | $524.13 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $418.98 | 2020-2024 | Ubrelvy, Viberzi, Linzess |
| Horizon Therapeutics Plc | $252.87 | 2019-2022 | |
| Exact Sciences Corporation | $219.57 | 2023-2024 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $165.30 | 2020-2022 | |
| Pfizer INC. | $123.18 | 2019-2024 | |
| Esperion Therapeutics, INC. | $122.00 | 2021-2022 | |
| Astellas Pharma US INC | $114.11 | 2023-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $91.27 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $88.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $60.91 | 2021-2024 | |
| Abbott Laboratories | $57.05 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Genentech USA, INC. | $56.89 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $56.17 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $52.99 | 2022 | |
| Arbor Pharmaceuticals, INC. | $48.03 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.41 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $41.50 | 2022-2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $37.47 | 2019-2021 | |
| Allergan, INC. | $32.06 | 2019-2020 | |
| Zyla Life Sciences, INC. | $31.96 | 2019 | |
| Ethicon US, LLC | $23.15 | 2020 | |
| Radius Health, INC. | $16.26 | 2020 | |
| Phadia US INC. | $15.79 | 2020 | |
| Corcept Therapeutics | $15.72 | 2025 | Korlym |
| Eisai INC. | $11.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Camayd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.